Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MGRX, unsubscribe in one click. Privacy
MGRX holds $481,281 in cash and short-term investments and burns about $380,262/quarter from operations, an estimated runway of 3.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 75 · High
These factors raise substantial doubt about the ability of the Company to continue as a going concern.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MGRX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | Institution (13F) | 1,536,000 | 7.12% | 2025-12-31 |
| Vanguard Group Inc | Institution (13F) | 489,532 | 2.27% | 2025-12-31 |
| Ikarian Capital, LLC | Institution (13F) | 138,146 | 0.64% | 2025-12-31 |
| Geode Capital Management, LLC | Institution (13F) | 108,322 | 0.50% | 2025-12-31 |
| Jane Street Group, LLC | Institution (13F) | 47,503 | 0.22% | 2025-12-31 |
| UBS Group AG | Institution (13F) | 46,167 | 0.21% | 2025-12-31 |
| Boothbay Fund Management, LLC | Institution (13F) | 38,441 | 0.18% | 2025-12-31 |
| Northern Trust Corporation | Institution (13F) | 37,579 | 0.17% | 2025-12-31 |
| Ackerman Capital Advisors, LLC | Institution (13F) | 34,500 | 0.16% | 2025-12-31 |
| Virtu Financial LLC | Institution (13F) | 33,462 | 0.16% | 2025-12-31 |
Share count 21,567,422 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-03-16 filed 2026-03-20 |
Cohen Jacob D. |
Option award (A) | 2,000,000 | – | – |
| 2026-03-16 filed 2026-03-20 |
Cohen Jacob D. |
Returned to issuer (D) | 2,000,000 | – | – |
| 2026-03-16 filed 2026-03-20 |
Cohen Jacob D. |
Option award (A) | 83,333 | – | – |
| 2026-03-16 filed 2026-03-20 |
Cohen Jacob D. |
Returned to issuer (D) | 83,333 | – | – |
| 2026-03-16 filed 2026-03-20 |
Cohen Jacob D. |
Option award (A) | 50,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MGRX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →